Benralizumab Receives FDA Approval as Add-On Maintenance The

The FDA approval of benralizumab for patients ages 6 to 11 with asthma follows the conclusions of the phase 3 TATE study.

Related Keywords

Japan , United States , American , Japanese , Liz Bodin , Lynda Mitchell , Allergy Asthma Network , Drug Administration , Astrazeneca , Asthma Network , Fda , Fenasra , Benralizumab , Asthma , Aged 6 , Maintenance ,